AstraZeneca, Isis unite to develop antisense cancer drugs

12/12/2012 | Reuters · Genetic Engineering & Biotechnology News

Isis Pharmaceuticals and AstraZeneca agreed to jointly discover and develop antisense treatments against five cancer targets. The agreement also covers rights to develop and market Isis' experimental drug ISIS-STAT3Rx, which is in Phase I development for patients with advanced lymphomas. The deal entitles Isis to $31 million upfront and near-term fees, plus potential licensing and milestone payments and sales royalties.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA